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Loss-of-function mutations in the PINK1 gene lead to recessive forms of Parkinson’s disease. Animal
models with depleted PINK1 expression have failed to reproduce significant nigral dopaminergic neu-
rodegeneration and clear alpha-synuclein pathology, main characteristics of the disease. In this study, we
investigated whether alpha-synuclein pathology is altered in the absence of PINK1 in cell culture and
in vivo. We observed that downregulation of PINK1 enhanced alpha-synuclein aggregation and apoptosis
in a neuronal cell culture model for synucleinopathy. Silencing of PINK1 expression in mouse substantia
nigra using recombinant adeno-associated viral vectors did not induce dopaminergic neurodegeneration
in a long-term study up to 10 months, nor did it enhance or accelerate dopaminergic neurodegeneration
after alpha-synuclein overexpression. However, in PINK1 knockout mice, overexpression of alpha-
synuclein in the substantia nigra resulted in enhanced dopaminergic neurodegeneration as well as
significantly higher levels of alpha-synuclein phosphorylation at serine 129 at 4 weeks postinjection. In
conclusion, our results demonstrate that total loss of PINK1 leads to an increased sensitivity to alpha-
synuclein-induced neuropathology and cell death in vivo.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Parkinson’s disease (PD) is the most prevalent human neuro-
degenerative movement disorder, affecting 1%e2% of the world-
wide population aged older than 65 years. PD is characterized by
the selective and progressive loss of the dopaminergic neurons of
the substantia nigra (SN), which results in major motor symptoms
such as bradykinesia, muscular rigidity, resting tremor, and gait
disturbances. Another neuropathologic cardinal feature of the dis-
ease is the presence of alpha-synuclein (a-synuclein)-rich in-
clusions, named Lewy bodies (LBs), in the surviving neurons
(Spillantini et al., 1997).
PD was long considered a sporadic disease with aging and
environmental toxins as its main risks factors. However, over the
past decade, mutations in several genes, among which a-synucleinbiology and Gene Therapy,
cijnenvoer 33 Box 7001,
16336336.
e (V. Baekelandt).
ll rights reserved.and PINK1, have been identified in inherited PD (Farrer, 2006;
Gasser, 2009). These genetic forms of the disease account for
5%e10% of the total cases of PD and share features with the sporadic
forms of the disease. Although the etiology of PD remains unclear,
mounting evidence suggests a similar mechanistic pathway leading
to the dopaminergic cell death at the origin of both idiopathic and
familial forms of PD, including protein misfolding, mitochondrial
dysfunction, and oxidative stress (Dawson and Dawson, 2003). For
this reason, gaining knowledge into the molecular basis of the
monogenic forms of PD may facilitate the understanding of the
more common sporadic forms of the disease.
Loss-of-function mutations in the gene encoding PINK1 (PTEN-
induced kinase 1) lead to autosomal recessive PD and have also
been identified as a cause of sporadic PD (Valente et al., 2004a,
2004b). The PINK1 gene is located in the PARK6 locus and en-
codes a highly conserved putative serine and/or threonine kinase.
Because of the presence of an N-terminal mitochondrial targeting
motif, the protein localizes predominantly to the mitochondria,
possibly with its kinase domain facing the cytoplasm, allowing
possible interactions with cytosolic proteins (Zhou et al., 2008).
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oxidative stress. It has been shown in cells that overexpression of
wild-type (WT) PINK1, but not of its PD-associated mutants, pro-
tects against apoptosis induced by proteasome inhibition, oxidative
stress, and mitochondrial toxins (Deng et al., 2005; Haque et al.,
2008; Klinkenberg et al., 2010; Plun-Favreau et al., 2007; Pridg-
eon et al., 2007; Sandebring et al., 2009; Valente et al., 2004b). More
recently, PINK1 was demonstrated to play a crucial role in
mitophagy, a cellular process by which mitochondrial structural
unity is maintained through selective autophagic clearance of
damaged mitochondria (Geisler et al., 2010; Matsuda et al., 2010;
Narendra et al., 2010).
Since the exact molecular mechanism by which PINK1-related
effects occur remains largely elusive, several PINK1 loss-
of-function animal models have been developed in the past years
to contribute to the understanding of human PD. Intriguingly,
although fly models lacking PINK1 expression display a drastic
phenotype, ranging from mitochondrial dysfunction to significant
dopaminergic neurodegeneration and motor deficits (Clark et al.,
2006; Park et al., 2006), the PINK1 knockout and knockdown
mouse models developed so far display mild neurodegenerative
changes (see, Oliveras-Salvá et al., 2011 for a review). Furthermore,
they do not reproduce the main hallmarks of PDd the progressive
dopaminergic cell loss in the SN and the presence of LB-like pa-
thology. In this context, increased a-synuclein aggregation was
reported in synucleinopathy cell culture models in which PINK1
was silenced via RNA interference (Liu et al., 2009) but an elaborate
study of a-synuclein toxicity in rodents is still missing.
In the present study, we investigated whether a-synuclein pa-
thology differs in the absence of PINK1 in cell culture and in vivo.
First, we showed that the downregulation of PINK1 enhances
a-synuclein aggregation and cell death in our synucleinopathy cell
culture model. Next, we generated PINK1 knockdownmice by local
delivery of a rAAV2/7-mediated, microRNA-based, short-hairpin
RNA against PINK1, which we have recently optimized to achieve
the most potent knockdown (Heeman et al., 2011; Osorio et al.,
2014). We observed that the prolonged downregulation of PINK1
in mouse SN did not induce dopaminergic cell death in a long-term
study up to 10 months. We examined the vulnerability of the nigral
dopaminergic neurons to a-synuclein toxicity when the PINK1
levels were reduced or absent. For this approach, we delivered a
rAAV2/7-a-synuclein WT vector to the SN of both PINK1 knock-
down and PINK1 knockout mice. Our data show that a-synuclein-
induced neurodegeneration and neuropathology is enhanced in the
PINK1 knockout mice but not after local knockdown in mouse SN.
2. Methods
2.1. Lentiviral vector design and production
Lentiviral (LV) vectors encoding for a-synuclein, PINK1 knock-
down, or the empty plasmid pCHMWS-blasticidin (control), under
the control of the cytomegalovirus promoter, were prepared in-
house as described earlier with the triple transfection method
(Geraerts et al., 2005). The knockdown construct was generated
using 2 repeats of a microRNA-based, short-hairpin RNA, hereafter
referred to as miR, against PINK1 messenger RNA (mRNA). The
artificial multiple-miR hairpins were generated using a micro-
RNA30 scaffold as previously described (Sun et al., 2006), in which
the target sequence was replaced by 2 miR repeats of a functional
short-hairpin sequence against PINK1 previously published (Zhou
et al., 2007). Detailed cloning, efficiency, and functionality of the
newly generated PINK1 knockdown construct in cell culture has
been shown elsewhere (Heeman et al., 2011; Osorio et al., 2014).
The LV vectors induced co-expression of the hygromycin selectionmarker (for a-synuclein) from the same transcript via an internal
ribosome entry site or blasticidin (for PINK1 knockdown and
control).
2.2. Generation of polyclonal stable overexpression cell lines using
LV vectors
Human neuroblastoma SH-SY5Y cells were grown in Dulbecco
modified Eagle medium (DMEM, Invitrogen) supplemented with
15% heat-inactivated fetal calf serum (Sigma), 50 mg/mL gentamycin
(Invitrogen), and 1% nonessential amino acids (Invitrogen) referred
to herein as DMEM-complete, at 37 C and 5% CO2 in a humidified
atmosphere. Transduction was performed as previously described
(Deleersnijder et al., 2011).
2.3. Synucleinopathy cell culture model
We used the cell culture model described by Ostrerova-Golts
et al. (2000) with minor modifications as previously described
(Gerard et al., 2010). Briefly, cells were treated for 72 hours with
100 mM H2O2 and 5 mM freshly prepared FeCl2 in DMEM-complete
and filtered through a 0.20-mm filter (Corning Inc, New York, NY,
USA). After 3 days, cells were washed with phosphate-buffered
saline (PBS) and fixed with 4% formaldehyde for 15 minutes. Cells
were stored in PBS until analysis.
2.4. High-content analysis of a-synuclein aggregation and cell
death
To quantify a-synuclein aggregation and apoptosis in our syn-
ucleinopathy cell culture model, we used the IN Cell Analyzer 1000
and IN Cell Investigator software (GE Healthcare) as described
before (Gerard et al., 2010).
2.5. Recombinant adeno-associated viral vector design and
production
The plasmids for the rAAV vector production were previously
described (Gao et al., 2005). These plasmids include the construct
for the AAV2/7 serotype, the AAV transfer plasmid, and the pAdv-
DeltaF6 adenoviral helper plasmid. The transfer plasmid encoded
either 2 miR repeats against the monomeric red fluorescent protein
(miR-ctrl) or against PINK1 (miR-PINK1) preceded by the enhanced
green fluorescent protein (eGFP), or the human WT a-synuclein
transgene. The transfer plasmid also contained the CMVie-
enhanced synapsin1 promoter to drive transgene expression and
the woodchuck hepatitis posttranscriptional regulatory element.
The viral vectors were produced at the Leuven Viral Vector Core
from the KU Leuven (Leuven, Belgium). Vector production and
purification were performed as described in detail elsewhere (Van
der Perren et al., 2011). The final titers of the concentrated vector
stocks ranged between 6.4  1011 and 2.4  1012 genome copies per
milliliter (GC/mL) as determined by quantitative polymerase chain
reaction.
2.6. Stereotactic surgery
Housing and handling of mice was done in compliance with the
European Communities Council Directive of November 24, 1986
(86/609/EEC) and approved by the Bioethical Committee of the KU
Leuven. We have previously described the generation of PINK1
knockout mice (PINK1/) and their control littermates (PINK1þ/þ)
(Heeman et al., 2011). Female, 8-week-old, C57BL/6 mice were
injected with rAAV2/7-miR-ctrl or rAAV2/7-miR-PINK1 vector
diluted at 1.5  1011 GC/mL. The human WT a-synuclein rAAV2/7
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animals were anaesthetized and placed in a stereotactic head frame
(Stoelting, IL, USA). After making a midline incision of the scalp, a
burr hole was drilled in the appropriate location for the SN at the
right site of the skull. Two microliters of viral vector were injected
at a rate of 0.25 mL/minwith a 30-gauge needle on a 10 mL Hamilton
syringe. The needle was left in place for an additional 5 minutes
before being slowly withdrawn from the brain. Coordinates for
mouse SN were anteroposterior (3.1 mm) and mediolateral
(1.2 mm) relative to bregma, and dorsoventral (4.0 mm) from
the dural surface (Paxinos and Franklin, 2001). Coordinates for
mouse striatum (STR) were anteroposterior (þ0.5 mm), medio-
lateral (2.0 mm), and dorsoventral (3.0 mm).
2.7. Cylinder test
To examine side bias in spontaneous forelimb use, mice were
placed individually inside a glass cylinder (12 cm diameter, 22 cm
height) which was positioned in front of 2 vertical mirrors to be
able to view the mouse from all angles. No habituation of the ani-
mals to the testing cylinder was allowed before video-recording.
Video-recordings were examined by an observer blinded to the
animal’s identity to count the number of supporting wall touches
(contacts with fully extended digits) executed independently with
the forelimb ipsilateral and contralateral to the lesion.
2.8. In situ hybridization
Sequences of antisense and sense digoxigenin-labeled ribop-
robes and production using T3 and T7 transcription systems and
1 mg of linearized plasmid were previously described (Taymans
et al., 2006). Briefly, mouse frozen brains were sectioned at 12 mm
thickness in a cryostat (Cryocut 1800; Cambridge Instruments,
Heidelberg, Germany). After hybridization, immunodetection was
performed using alkaline phosphatase-conjugated anti-digox-
igenin Fab fragments (1:4000, Roche Diagnostics). Nitroblue
tetrazolium and/or bromo-chloro-indolylphosphate (NBT/BCIP,
Roche Diagnostics) was used as chromogen. As a control of probe
specificity, sections hybridized with antisense probe were accom-
panied by adjacent sections hybridized with sense riboprobe. No
significant labeling was observed (Supplementary Fig. 2A). The in
situ hybridization (ISH) signal was assessed by densitometric
analysis using the Image J software (Version 1.45s, NIH, Bethesda,
MD, USA). The average densities of striatal or nigral fields in both
contralateral and ipsilateral sides were determined. Percentage
signal was calculated as ratio of the signal in the ipsilateral versus
contralateral side and multiplied by 100.
2.9. Histology
At selected time points, mice were deeply anesthetized using an
overdose of pentobarbital (Nembutal, CEVA Santé, Belgium) and
transcardially perfused with saline followed by ice-cold 4% para-
formaldehyde in PBS. Immunohistochemistry was performed under
uniform conditions on free-floating 50-mmethick coronal brain
sections using antibodies raised against GFP (1:10,000, in house),
tyrosine hydroxylase (TH, 1:5000, Millipore 152), VMAT-2 (1:1000,
abcam 81,855), a-synuclein (1:5000, Millipore 5038), and P-S129 a-
synuclein (1:5000, Elan Pharmaceuticals; Anderson et al., 2006;
George et al., 2010). After 3% hydrogen peroxide treatment, sec-
tions were incubated overnight in primary antibody solution in 10%
normal goat serum (DakoCytomation, Belgium). As secondary anti-
body, we used biotinylated anti-rabbit or anti-mouse IgG (1:600,
DakoCytomation), followed by incubation with streptavidin-
horseradish peroxidase complex (1:1000, DakoCytomation). THimmunoreactivity was visualized using Vector SG (SK-4700, Vector
Laboratories) as chromogen; GFP and (P-S129) a-synuclein immu-
noreactivities were visualized using 3,3-diaminobenzidine (0.4 mg/
mL, Sigma-Aldrich). After being rinsed and mounted, the sections
were cover-slipped using DPX mounting medium (Sigma).
For fluorescent double staining, sections were rinsed 3 times in
PBS and incubated overnight in the dark in PBS-0.1% Triton X-100,
10% goat or donkey serum, and the following antibodies: chicken
anti-GFP (1:500, Aves Labs 1020), rabbit anti-a-synuclein (1:1000,
Millipore 5038), and mouse anti-TH (1:1000, Millipore MAB318), or
mouse anti-a-synuclein (1:100, Invitrogen LB309) and rabbit anti-
ubiquitin (1:1000, Dako 20,458). After rinsing, the sections were
incubated in the dark for 1 hour in fluorochrome-conjugated sec-
ondary antibodies such as donkey anti-chicken FITC (1:400, Lucron),
donkey anti-rabbit Alexa 647, and donkey anti-mouse Alexa 555
(1:400,Molecular Probes, Invitrogen), or goat anti-mouse Alexa 488
andgoat anti-rabbit Alexa633 (1:400,Molecular Probes, Invitrogen).
After being rinsed and mounted, the sections were cover-slipped
with Mowiol (Sigma).
2.10. Stereological quantification and confocal microscopy
The number of TH-, a-synuclein-, and P-S129 a-synuclein-pos-
itive cells in the SN was estimated using a random sampling ste-
reological counting method, the optical fractionator (Schmitz and
Hof, 2005), in a computerized system (StereoInvestigator; Micro-
BrightField, Magdeburg, Germany). Coefficient of error attributable
to the sampling was calculated according to Gundersen and Jensen
(1987). Errors 0.10 were accepted. For each animal, every fourth
section throughout the rostro-caudal extent of the SN was incor-
porated to the counting procedure. The SN was delineated
from2.54 to3.88mm posterior to bregma. The conditions of the
experiment were blinded to the investigator. The number of a-
synuclein-positive cells in the SN exhibiting LB-like aggregates in
the cytoplasm was determined using the optical fractionator at the
100 magnifying lens. Each cell was visually scored for the pres-
ence or the absence of aggregates. Examples of an a-synuclein-
positive cell without and with aggregates are displayed in Fig. 6B
and C, respectively.
Fluorescent triple immunostaining for a-synuclein, GFP, and TH
or double immunostaining for a-synuclein and ubiquitin were
visualized by confocal laser scanning microscopy (Fluoview 1000,
Olympus).
2.11. Statistical analysis
Statistical analysis was performed using the GraphPad Prism 5.0
software package. Results are expressed as means  standard error
of the mean. For the cell culture assay, the nonparametric Kruskal-
Wallis test was used followed by a posttest (Dunn) to correct for
multiple testing. As for the stereological quantifications, statistical
significance was assessed using the Student t-test or 2-way analysis
of variance followed by Bonferroni post hoc test for intergroup
comparisons. Statistical significance level was set as follows: * if p<
0.05, ** if p < 0.01, and *** if p < 0.001.
3. Results
3.1. Downregulation of PINK1 enhances a-synuclein-induced
aggregation and cell death in a synucleinopathy cell culture model
We have previously optimized a neuronal cell culture assay in
which oxidative stress produced by FeCl2 and H2O2 stimulates a-
synuclein aggregation (Gerard et al., 2010). To investigate the effect
of the absence of PINK1 in this synucleinopathy model, we
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LV vector encoding a control plasmid or 2 miRNA-based, short-
hairpin RNA repeats (miR) against PINK1 (PINK1 knockdown).
Knockdown of PINK1 expression was confirmed using a quantita-
tive real-time polymerase chain reaction (Fig.1A).We observed that
the downregulation of PINK1 by means of an LV vector significantly
increased the aggregation of a-synuclein in the synucleinopathy
cell culture model when compared with control (Fig. 1B). In addi-
tion, we determined the effect of PINK1 knockdown on nucleus
condensation and fragmentation as a measure for cell death
(Fig. 1C). Similarly, to the effect on a-synuclein aggregation, the
downregulation of PINK1 enhanced the number of late apoptotic
cells when compared with control.3.2. rAAV2/7 vector-mediated knockdown of PINK1 in mouse SN
does not cause behavioral deficits or dopaminergic cell death
To examine whether the downregulation of PINK1 influences a-
synuclein neuropathology in vivo, we first studied PINK1 knock-
down by itself in adult mouse brain. For this approach, we used the
same PINK1 knockdown construct as previously developed in an LV
vector for the cell culture assay but now delivered it in mouse SN in
the context of a rAAV2/7 vector.
To evaluate the efficacy of our viral vector to silence PINK1
expression in mouse STR and SN, we used ISH because of the lack of
reliable and sensitive PINK1 antibodies available for immunohis-
tochemical detection of endogenous mouse PINK1. At 2 weeks after
injection of the rAAV2/7-miR-PINK1 or rAAV2/7-miR-ctrl in mouse
STR or SN, brain tissues were processed for ISH. We observed a
robust reduction in the PINK1 signal with the rAAV2/7-miR-PINK1
when compared with the contralateral side or the injected side of
rAAV2/7-miR-ctrl (Fig. 2A). Only 23% of PINK1 mRNA in the STR and
9% in the SN remained at 2 weeks after injection when transgene
expression is known to be maximal (Fig. 2B).
Next, we performed a long-term follow-up study of the down-
regulation of PINK1 in mouse SN. We assessed behavioral perfor-
mance in the cylinder test at 1, 4, 6, 8, and 10 months postinjection
(Fig. 2C). All groups performed similarly and no impairment was
observed. We also monitored the weight of these animals and no
differences were observed between groups (data not shown). In
addition, we stained the nigral dopaminergic neurons for the
dopaminergic marker TH, to evaluate their survival upon PINK1
silencing (Fig. 2E). Stereological quantification of the number of TH-
positive neurons in the SN showed no differences over time be-
tween groups (Fig. 2D), indicating that PINK1 downregulation by
itself does not induce dopaminergic neurodegeneration. Because
both knockdown viral vectors contained the same reporter gene,
we performed immunohistochemical stainings for GFP, whichFig. 1. Downregulation of PINK1 enhances a-synuclein aggregation and cell death in cell cul
or a PINK1 knockdown LV vector. High-content analysis of (B) a-synuclein aggregation and
neuroblastoma SH-SY5Y cells overexpressing a-synuclein and transduced with a control or PI
Quantitative PCR. *p < 0.05, **p < 0.01, ***p < 0.001.enabled us to demonstrate stable transgene expression in the
injected area over time (Fig. 2F).3.3. Local PINK1 knockdown in mouse SN does not enhance
a-synuclein-induced neuropathology
We have previously characterized the delivery of a rAAV2/7-a-
synucleinWT vector in adult mouse SN (Oliveras-Salva et al., 2013).
We observed that the overexpression of a-synuclein led to a strong
and progressive dopaminergic neuron loss in mouse SN, which
ranged from 19% to 57% cell death at 4 weeks after injection,
depending on the vector dose. In the present study, we used the
intermediate vector dilution of the past study for the over-
expression of a-synuclein (4.0  1011 GC/mL) that induced 45% TH-
positive cell loss at 4 weeks postinjection. We chose this dose
because we reasoned that a slow progression of the neuro-
degeneration might easily allow us to distinguish possible differ-
ences between groups.
To investigate whether a-synuclein-induced dopaminergic
neurodegeneration differs when PINK1 is downregulated, we
unilaterally coinjected the rAAV2/7-a-synuclein WT vector
together with the rAAV2/7-miR-ctrl vector or rAAV2/7-miR-PINK1
vector in mouse SN. We performed fluorescent triple immunos-
tainings to assess the expression of both transgenes. At 5 days
postinjection, we observed a widespread expression of both a-
synuclein and GFP proteins in the injected area (Fig. 3A). Co-
localization of a-synuclein and GFP with TH indicated an efficient
transduction of the targeted nigral dopaminergic neurons distrib-
uted throughout the SN pars compacta.
We assessed the behavioral performance of the mice in the
cylinder test at 5 days and 4 weeks postinjection (Fig. 3B). All
groups behaved similarly and no clear impairments were observed.
Next, we performed immunohistochemical stainings for TH in the
SN (Fig. 3C). We observed a progressive and significant dopami-
nergic cell loss over time in both groups, which is consistent with
the localized overexpression of rAAV2/7-a-synuclein in mouse SN
(Fig. 3D). However, no clear differences in the percentage of
remaining TH-positive neurons were observed when PINK1 was
downregulated compared with controls (miR-ctrl: 23% at 2 weeks
and 46% at 4 weeks; miR-PINK1: 26% at 2 weeks and 49% at
4 weeks) (Fig. 3E). To confirm the dopaminergic cell loss and not a
TH downregulation we performed a staining for VMAT, another
dopaminergic marker. This marker also showed a reduced staining
in the SN of the injected side compared with the non-injected side
(Supplementary Fig. 3).
To evaluate the expression of the transgene over time in the
injected region, we performed immunohistochemical stainings for
human a-synuclein. We observed a clear increase in a-synucleinture. (A) Reduced PINK1 mRNA levels in SH-SY5Y cells after transduction with a control
(C) nucleus fragmentation after 3 days of oxidative stress (FeCl2 and H2O2) in human
NK1 knockdown LV vector. Abbreviations: LV, lentiviral; mRNA, messenger RNA; Q-PCR,
Fig. 2. Efficient and stable rAAV2/7 vector-mediated knockdown of PINK1 in mouse SN does not induce behavioral impairment or dopaminergic cell loss. (A) Representative images
of the STR and the SN of control (miR-ctrl) and PINK1 knockdown (miR-PINK1) mice reveal potent knockdown of PINK1 in the injected side at 2 weeks postinjection. Scale bar ¼
100 mm. (B) Percentage of ISH PINK1 intensity signals in STR and SN (n ¼ 3). (C) Performance in the cylinder test shows no asymmetry in the use of the contralateral paw over time
neither in miR-ctrl mice nor in miR-PINK1 mice (n ¼ 5; m: month(s)). (D) Stereological quantification of the number of TH positive cells in the SN at 1, 4, and 10 months postinjection
reveals no dopaminergic cell loss in the injected side of miR-ctrl mice or miR-PINK1 mice over time (n ¼ 5). (EeF) Representative images of (E) TH and (F) GFP immunostainings of
the injected and non-injected sides of miR-ctrl and miR-PINK1 mice at 1, 4, and 10 months postinjection. Both rAAV knockdown vectors contain GFP to allow for demonstration of
stable transgene expression over time. Scale bars ¼ 250 mm. Abbreviations: Inj, injected side; N-inj, non-injected side; SN, substantia nigra; STR, striatum; TH, tyrosine hydroxylase.
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decrease at 4 weeks postinjection to a similar extent for both
knockdown viral vectors (Fig. 4A). Quantification of the total
number a-synuclein-positive cells in the SN did not reveal signifi-
cant differences in a-synuclein expression between groups at any of
the 3 different time points (Fig. 4C).
In parallel, we performed immunohistochemical stainings for
P-S129 a-synuclein (Fig. 4B). This phosphorylated form of a-
synuclein at serine residue at position 129 (P-S129) mainly ac-
cumulates in the LBs (Anderson et al., 2006; Fujiwara et al.,
2002), thus, it is considered as a neuropathologic marker for a-
synuclein. Overall, we observed a net increase in the number of
P-S129 a-synuclein-positive cells in the SN at 4 weeks post-
injection for both knockdown conditions without cleardifferences between groups (Fig. 4D). When calculating the
percentage of P-S129 a-synuclein-positive cells in the SN by
determining the ratio between the number of P-S129 a-synu-
clein-positive cells (Fig. 4D) and the total number of a-synuclein-
positive cells (Fig. 4C) estimated in the SN, the PINK1 knockdown
condition displayed an enhanced increase in the percentage of P-
S129 a-synuclein-positive cells in the SN, although this was not
significant (Fig. 4E). In conclusion, these results indicate that a-
synuclein-induced dopaminergic neurotoxicity is not signifi-
cantly altered when PINK1 is downregulated. Also, at a later time
point of 4 months postinjection, no significant differences in
behavioral performance, dopaminergic cell survival, or a-synu-
clein expression were observed between groups (data not
shown).
Fig. 3. Knockdown of PINK1 in mouse SN does not enhance nigral dopaminergic neurodegeneration upon a-synuclein overexpression. (A) Representative confocal images of
fluorescent triple immunostainings for a-synuclein (blue), GFP (green), and TH (red) show extensive co-localization (merge) in the dopaminergic neurons of the injected side at
5 days after co-injection. Scale bar ¼ 200 mm. (B) Performance in the cylinder test of miR-ctrl and miR-PINK1 mice at 5 days (n ¼ 4) and 4 weeks (n ¼ 10) after injection. (C)
Representative images of TH immunoreactive neurons in the SN injected with miR-ctrl and miR-PINK1 rAAV2/7 vectors after 5 days, 2 weeks, and 4 weeks. Note that overexpression
of a-synuclein induces a progressive TH cell loss over time independent of the knockdown vector. The absence of dopaminergic neurodegeneration in the non-injected side at
4 weeks postinjection. Right panels are magnifications of the overview (left panels). Scale bars ¼ 200 mm. (D) Stereological quantification of the number of TH positive neurons in the
SN of miR-ctrl and miR-PINK1 mice at 5 days (n ¼ 4), 2 weeks (n ¼ 10), and 4 weeks (n ¼ 10) postinjection. (E) Percentage of remaining TH-positive neurons in the injected SN of
miR-ctrl and miR-PINK1 mice. Abbreviations: Inj, injected side; N-inj, non-injected side; SN, substantia nigra; TH, tyrosine hydroxylase. **p < 0.01, ***p < 0.001. (For interpretation of
the references to color in this figure, the reader is referred to the web version of this article.)
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phosphorylation in PINK1 knockout mice
Next to the simultaneous delivery of rAAV2/7-a-synuclein with
the PINK1 knockdown vector, we unilaterally injected the a-synu-
clein overexpressing viral vector in the SN of PINK1 knockout mice
(PINK1/) and theirWTage-matched control littermates (PINK1þ/þ),
which were previously developed by our group (Heeman et al.,
2011). To examine the susceptibility of the PINK1 knockout
mice to a-synuclein-induced toxicity, we performed immuno-
histochemical stainings for TH at 5 days, 2 weeks, 4 weeks, and
9 weeks after injection (Fig. 5A). In agreement with the rate ofneurodegeneration induced in the PINK1 knockdown or control
groups described previously, we observed a progressive and
significant loss of the nigral dopaminergic neurons over time in
both groups (Fig. 5B). Stereological quantification of the
remaining TH-positive neurons showed a differential degree of
TH cell loss between groups (Fig. 5C). At 4 weeks after injection,
stereological counts revealed a 36% TH-positive neuron loss
respective to the contralateral side in WT mice, whereas 49% of
the TH-positive nigral cells were lost in the PINK1 knockout
mice. A similar trend was observed at 9 weeks postinjection,
although this difference was not significant (PINK1þ/þ: 53%;
PINK1/: 60%).
Fig. 4. Total and P-S129 a-synuclein expression after rAAV2/7 vector-mediated a-synuclein overexpression combined with PINK1 knockdown. Representative images of (A) a-
synuclein and (B) P-S129 a-synuclein immunostainings in the SN of miR-ctrl and miR-PINK1 mice at 5 days, 2 weeks, and 4 weeks after injection. The absence of immunoreactivity
in the contralateral SN at (A) 2 weeks and (B) 4 weeks after injection when expression is maximal. Right panels are magnifications of the overview (left panels). Scale bars ¼ 200 mm.
(C) Stereological quantification of the number of a-synuclein and (D) P-S129 a-synuclein positive cells in the SN injected with miR-ctrl and miR-PINK1 rAAV2/7 vectors at 5 days (n ¼
4), 2 weeks (n ¼ 10), and 4 weeks (n ¼ 10) postinjection; d indicates days and w indicates weeks. (E) Percentage of P-S129 a-synuclein positive cells in the injected SN. Asterisks (*)
depict significant increase respective to 5 days, unless specified otherwise. Abbreviations: N-inj, non-injected side; SN, substantia nigra. *p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 5. PINK1 knockout mice display a higher loss of nigral dopaminergic neurons upon a-synuclein overexpression. (A) Representative images of TH immunoreactive neurons in the
injected SN of PINK1þ/þ and PINK1/ mice at 5 days, 2 weeks, 4 weeks, and 9 weeks after injection. Overexpression of a-synuclein induces a progressive TH cell loss over time
independent of the genotype. Note the absence of dopaminergic neurodegeneration in the contralateral side at 9 weeks postinjection when cell loss is maximal. Right panels are
magnifications of the overview (left panels). Scale bars ¼ 200 mm. (B) Stereological quantification of the number of TH-positive neurons in the SN of PINK1þ/þ and PINK1/mice at
5 days (n ¼ 7), 2 weeks (n ¼ 5), 4 weeks (n ¼ 18e20), and 9 weeks (n ¼ 6e8) postinjection. (C) Percentage of remaining TH positive neurons in the injected SN of PINK1þ/þ and
PINK1/ mice. Abbreviations: Inj, injected side; N-inj, non-injected side; SN, substantia nigra; TH, tyrosine hydroxylase.
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evaluate the expression of the transgene over time in the injected
region. As expected, we observed an increase in expression until
2 weeks postinjection, followed by a significant decrease at 4 weeks
after injection (Fig. 6A and E). Similarly to the dopaminergic cell
counts, we observed a more pronounced loss of a-synuclein-posi-
tive cells in PINK1 knockout mice when compared with their con-
trol littermates at 4 weeks postinjection (PINK1þ/þ: 3350  359;
PINK1/: 2781  449). A similar trend was observed at 9 weeks
postinjection, yet not significant (PINK1þ/þ: 2968  206; PINK1/:
2120  403). Interestingly, a-synuclein expression significantly
declined in PINK1 knockout mice at 9 weeks postinjection, whereas
the total number of a-synuclein-positive cells did not substantially
differ from 4 to 9 weeks postinjection in the WT group.
To investigate the pathologic nature of the remaininga-synuclein-
positive cells, we performed fluorescent double immunostainings for
a-synuclein and ubiquitin because immunohistochemical studies
have shown that ubiquitin is amajor constituent of the LB (Spillantini
et al., 1997). At 4 weeks postinjection, we visualized a clear co-
localization of a-synuclein and ubiquitin (Fig. 6D). In addition, we
examined a-synuclein-related pathology by means of 2 stereological
quantification methods. Firstly, we estimated the percentage of a-
synuclein-positive cells containing aggregates in the SN (Fig. 6FeH).
For this approach, we visually scored the nigral a-synuclein-positive
cells for the presence of LB-like inclusions in their cytoplasm at high
magnification. Examples of an a-synuclein-positive cell without and
with aggregates are displayed in Fig. 6B and C, respectively. We
observed a progressive increase over time in the percentage of
aggregate-positive cells in theSN forbothconditions. Thiswasslightly
enhanced in PINK1 knockoutmice throughout thewhole time courseof the experiment (PINK1þ/þ: 18% at 5 days, 22% at 2 weeks, 37% at
4weeks, and 50% at 9weeks; PINK1/: 21% at 5 days, 32% at 2weeks,
42% at 4 weeks, and 56% at 9 weeks) (Fig. 6F).
Subsequently, we stained for P-S129 a-synuclein in the SN and
we observed a progressive increase over time for both groups up to
4 weeks after injection (Fig. 7A and B). Likewise, the estimation of
the percentage of P-S129 a-synuclein-positive cells in the SN
revealed a gradual increase over time for both groups up to 4 weeks
postinjection (Fig. 7C). Interestingly, the 9 weeks time point
exhibited less P-S129 a-synuclein-positive cells for both conditions,
but it was more substantially reduced in the PINK1 knockout mice.
We have previously reported that a maximum is reached in the
number of P-S129 a-synuclein-positive cells following delivery of
this rAAV2/7-a-synuclein vector in mice, after which the vast cell
death (over 50% dopaminergic neuron loss) affects the P-S129 a-
synuclein counts (Oliveras-Salvá M. et al., 2013). The total number
and the percentage of phosphorylated S129 a-synuclein-positive
cells was significantly higher in the SN of PINK1 knockout mice
compared with WT mice at 4 weeks postinjection. In addition,
PINK1 knockout mice showed a trend to an enhanced increase in
the percentage of phosphorylated S129 a-synuclein-positive cells at
all time points (Fig. 7C). Taken together, these results indicate that
complete in vivo depletion of PINK1 sensitizes the dopaminergic
neurons to a-synuclein-induced cell death and neuropathology.
4. Discussion
The goal of the present study was to investigate whether a-
synuclein neuropathology differs in the absence of PINK1 in cell
culture and in vivo. We showed that the downregulation of
Fig. 6. PINK1 knockout mice show an enhanced a-synuclein cell loss and aggregation in SN. (A) Representative images of a-synuclein immunostainings in the SN of PINK1þ/þ and
PINK1/ mice at 5 days and 4 weeks after injection. Right panels are magnifications of the overview (left panels). Scale bars ¼ 200 mm. (BeC) High magnification pictures demonstrate
a-synuclein pathology in the SN. Scale bars ¼ 10 mm. (B) a-Synuclein positive cell without aggregates and (C) with aggregates (arrow). (D) Fluorescent double immunostaining for
a-synuclein (green) and ubiquitin (red) shows co-localization (merge) at 4 weeks postinjection. Scale bars ¼ 50 mm. (E) Stereological quantification of the number of a-synuclein positive
cells in the SN of PINK1þ/þ and PINK1/ mice at 5 days (n ¼ 7), 2 weeks (n ¼ 5), 4 weeks (n ¼ 18e20), and 9 weeks (n ¼ 6e8) postinjection; d indicates days w indicates weeks. (F)
Percentage of aggregate positive cells in the SN of PINK1þ/þ and PINK1/mice. (GeH) Absolute number of a-synuclein positive cells with and without aggregates in the SN of (G) PINK1þ/
þ and (H) PINK1/ mice. Abbreviation: SN, substantia nigra. (For interpretation of the references to color in this figure, the reader is referred to the web version of this article.)
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death in a neuronal cell culture model for synucleinopathy. This
result is in agreement with a previous study reporting that the
loss of PINK1 leads to increased detergent-insoluble aggregates
in a neuronal cell culture model overexpressing either WT or
A53T a-synuclein (Liu et al., 2009). In vivo, we reported
that PINK1 knockdown does not lead to dopaminergic cell death
by itself nor enhance the dopaminergic neurodegeneration
induced by rAAV2/7 vector-mediated overexpression of WT a-
synuclein. In contrast, we observed that PINK1 knockout miceare more vulnerable to a-synuclein-induced cell death and
neuropathology.
The identification of gene mutations leading to rare Mendelian
forms of PD has impelled the development of several animal
models. In the case of PINK1, fly, worm, and fish models exhibit a
robust phenotype with neurodegeneration, motor deficits, mito-
chondrial impairment, and vulnerability to toxins (Anichtchik et al.,
2008; Park et al., 2006; Sallinen et al., 2010; Samann et al., 2009; Xi
et al., 2010; Yang et al., 2006). Conversely, PINK1 knockout and
knockdown mice developed so far are characterized by a mild
Fig. 7. PINK1 knockout mice display a different pattern in P-S129 a-synuclein expression after rAAV2/7-a-synuclein delivery to the SN. (A) Representative images of P-S129
a-synuclein expression in the SN of PINK1þ/þ and PINK1/ mice at 5 days, 2 weeks, 4 weeks, and 9 weeks after injection. Right panels are magnifications of the overview (left
panels). Scale bars ¼ 200 mm. (B) Stereological quantification of the number of P-S129 a-synuclein positive cells in the SN of PINK1þ/þ and PINK1/ mice (n ¼ 4). (C) Percentage of
P-S129 a-synuclein positive cells in the injected SN. Asterisks (*) depict significant increase respective to 5 days, unless specified otherwise. Abbreviation: SN, substantia nigra.
*p < 0.05, **p < 0.01, ***p < 0.001.
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stress-inducing toxins (Oliveras-Salvá et al., 2011). They do not
reproduce the main features of PDd the progressive degeneration
of the nigral dopaminergic neurons and the presence of cyto-
plasmic a-synuclein-rich inclusions. Only a nonsignificant increase
in a-synuclein protein levels but in contrast, a relevant decrease in
mRNA levels has been reported in the brain stem andmidbrain of 2-
year-old PINK1 knockout mice (Gispert et al., 2009). These results
suggest that a-synuclein degradation and resynthesis might be
impaired, indicating a hurdle in protein clearance. In patients with
sporadic PD and PD associated with heterozygous PINK1mutations,
PINK1 has been detected in LBs (Gandhi et al., 2006; Murakami
et al., 2007). The sole neuropathologic report from a PD patient
with homozygous PARK6 mutations showed that PINK1-linked PD
induces LB pathology (Samaranch et al., 2010).
We reasoned that adult knockdownof PINK1might induce amore
severe phenotype because of the acute nature of the knockdownwith
less opportunity for compensatory changes. Indeed, adult local loss of
parkin function was shown to result in dopaminergic cell loss after
10 months (Shin et al., 2011). In the past, we have used lentiviral
vectors for stable and long-term silencing of target genes in the cen-
tral nervous system using short-hairpin RNAs (Van den Haute et al.,
2003). RNA interference is a mechanism present in all eukaryotic
cells to halt the expression of targeted genes, which involves pro-
cessing of so-called microRNA structures (He and Hannon, 2004).
Thus, the use of artificial microRNAs might provide a better tool for
targeted gene silencing studies in vivo as they mimic the natural
process ongoing in the cell (McBride et al., 2008). In addition,wehave
shown that rAAV vectors efficiently transduce nigral dopaminergic
neurons (Van der Perren et al., 2011). Based on this, we selected the
rAAV2/7 serotype because of its high transduction efficiency of the
dopaminergic neurons invivo, andwe combined itwith anoptimized
miR-based construct (Heeman et al., 2011) (Osório et al., 2014). Here,we reported the development and characterization of a PINK1
knockdownmousebydeliveryofa specificmiR-based rAAV2/7vector.
We have successfully shown efficient knockdown of PINK1 both in
STR and SN of adult mouse. However, this did not induce dopami-
nergic neurodegeneration in the time scope of our study. Previous
studies have reported the absence of neurodegeneration in the SN of
PINK1knockoutmiceupto19monthsold (Akundiet al., 2011;Gispert
et al., 2009; Glasl et al., 2012; Kitada et al., 2007). A recent report
mimicking PINK1 loss-of-function via short-hairpin RNA adenoviral
vectordelivery inmousestriatumalso failed to reproduceasignificant
dopaminergic neurodegeneration (Haque et al., 2012). Taking into
account theroleofPINK1 inmitochondrial stability,wecannotdiscard
that the depletion of PINK1 expression might induce subtle cellular
modifications not visible at the phenotypic level.
PINK1 knockout mice have shown susceptibility to oxidative
stress and vulnerability to neurotoxins (Gautier et al., 2008; Haque
et al., 2008; Wang et al., 2011). In the present study, we evaluated
the effect of a-synuclein neurotoxicity in the absence of PINK1
in vivo via 2 parallel approaches.We injected a rAAV2/7-a-synuclein
vector in the SN of both PINK1 knockout and knockdown mice. We
have previously shown that delivery of rAAV2/7-a-synuclein vector
in mouse SN triggers a robust and progressive loss of dopaminergic
neurons, as well as marked a-synuclein-related neuropathology
(Oliveras-Salvá et al., 2013). We now report that the complete
ablation of PINK1 sensitizes the nigral neurons to a-synuclein
toxicity. Because rAAV2/7-a-synuclein induced the same rate of
neurodegeneration after local PINK1 knockdown as in the control
group, we suggest that the remaining PINK1 is sufficient tomaintain
the dopaminergic cell function within the time frame of our study.
Over the last years, much attention has been dedicated to the
study of mitochondrial dysfunction as an important cause of the
dopaminergic cell death seen in PD patients. To date, it is still un-
known how a-synuclein mediates its cytotoxic effects, but it
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and reduces mitochondrial complex I activity, indicating that a-
synuclein also regulates mitochondrial function and dynamics
(Devi et al., 2008; Parihar et al., 2008). Although the link between a-
synuclein pathology and mitochondrial dysfunction remains
unclear, several groups have demonstrated that, in pathologic
conditions, a-synuclein can translocate to the mitochondria via an
N-terminal mitochondrial targeting sequence, suggesting that it
might interfere with mitochondrial function (Cole et al., 2008; Devi
et al., 2008). In worms, mitochondrial fragmentation induced by
expression of a-synuclein is rescued by co-expression of PINK1
(Kamp et al., 2010). In flies, overexpression of PINK1 rescues motor
and developmental defects induced by a-synuclein (Todd and
Staveley, 2008, 2012). PINK1 plays a crucial role in mitochondrial
viability by the selective clearance of damaged mitochondria in
concert with parkin in a cellular autophagic process called
mitophagy (Geisler et al., 2010;Matsuda et al., 2010; Narendra et al.,
2010). In addition, PINK1 has been described to exert a neuro-
protective and pro-survival effect under situations of oxidative
stress-induced cell death via several proteins and pathways. Recent
findings have shown that the mitochondrial chaperone protein
TRAP1, substrate of PINK1, mitigates motor deficits and dopami-
nergic neurodegeneration in A53T a-synuclein-expressing flies
(Butler et al., 2012). Phosphorylation of TRAP1 by PINK1 protects
the mitochondria against cell death induced by oxidative stress and
prevents cytochrome c release from the mitochondria (Pridgeon
et al., 2007).
Taken together, we have shown that a-synuclein neuropa-
thology is exacerbated in the absence of PINK1. Whether there is a
direct interaction of PINK1 and a-synuclein awaits further research,
but our findings might help to elucidate the link between mito-
chondrial dysfunction and a-synucleinopathy in mammalian brain
and provide new therapeutic targets.
Disclosure statement
The authors declare that there are no actual or potential conflicts
of interest.
Acknowledgements
The authors thank Dr Annelies Michiels, Sylvie De Swaef, and
Nam-Joo Van der Veken for the rAAV vector production; and
Caroline van Heijningen for excellent technical assistance. They
thank Professor Johan Hofkens and Charlotte David for the use of
the confocal laser scanning microscope (Molecular Imaging and
Photonics, KU Leuven). This work was supported by the European
FP7 ITN NEUROMODEL (PITN-GA-2008e215618), the FP7 RTD
MEFOPA (HEALTH-2009e241791), the FWO Vlaanderen
(G.0768.10), the MJFox Foundation (Target validation 2010), the KU
Leuven (OT/08/052A), the Queen ElisabethMedical Foundation, and
the IWT-Vlaanderen (IWT/SBO 80020).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.neurobiolaging.
2014.04.032.
References
Akundi, R.S., Huang, Z., Eason, J., Pandya, J.D., Zhi, L., Cass, W.A., Sullivan, P.G.,
Bueler, H., 2011. Increased mitochondrial calcium sensitivity and abnormal
expression of innate immunity genes precede dopaminergic defects in Pink1-
deficient mice. PLoS One 6, e16038.Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J.,
Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P.S., Shen, X., Chataway, T.,
Schlossmacher, M.G., Seubert, P., Schenk, D., Sinha, S., Gai, W.P., Chilcote, T.J.,
2006. Phosphorylation of Ser-129 is the dominant pathological modification of
alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281,
29739e29752.
Anichtchik, O., Diekmann, H., Fleming, A., Roach, A., Goldsmith, P., Rubinsztein, D.C.,
2008. Loss of PINK1 function affects development and results in neuro-
degeneration in zebrafish. J. Neurosci. 28, 8199e8207.
Butler, E.K., Voigt, A., Lutz, A.K., Toegel, J.P., Gerhardt, E., Karsten, P., Falkenburger, B.,
Reinartz, A., Winklhofer, K.F., Schulz, J.B., 2012. The mitochondrial chaperone
protein TRAP1 mitigates alpha-synuclein toxicity. PLoS Genet. 8, e1002488.
Clark, I.E., Dodson, M.W., Jiang, C., Cao, J.H., Huh, J.R., Seol, J.H., Yoo, S.J., Hay, B.A.,
Guo, M., 2006. Drosophila pink1 is required for mitochondrial function and
interacts genetically with parkin. Nature 441, 1162e1166.
Cole, N.B., Dieuliis, D., Leo, P., Mitchell, D.C., Nussbaum, R.L., 2008. Mitochondrial
translocation of alpha-synuclein is promoted by intracellular acidification. Exp.
Cell Res. 314, 2076e2089.
Dawson, T.M., Dawson, V.L., 2003. Molecular pathways of neurodegeneration in
Parkinson’s disease. Science 302, 819e822.
Deleersnijder, A., Van Rompuy, A.S., Desender, L., Pottel, H., Buee, L., Debyser, Z.,
Baekelandt, V., Gerard, M., 2011. Comparative analysis of different peptidyl-
prolyl isomerases reveals FK506-binding protein 12 as the most potent
enhancer of alpha-synuclein aggregation. J. Biol. Chem. 286, 26687e26701.
Deng, H., Jankovic, J., Guo, Y., Xie, W., Le, W., 2005. Small interfering RNA targeting
the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys.
Res. Commun. 337, 1133e1138.
Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G., Anandatheerthavarada, H.K.,
2008. Mitochondrial import and accumulation of alpha-synuclein impair com-
plex I in human dopaminergic neuronal cultures and Parkinson disease brain.
J. Biol. Chem. 283, 9089e9100.
Farrer, M.J., 2006. Genetics of Parkinson disease: paradigm shifts and future pros-
pects. Nat. Rev. Genet. 7, 306e318.
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S.,
Shen, J., Takio, K., Iwatsubo, T., 2002. Alpha-synuclein is phosphorylated in
synucleinopathy lesions. Nat. Cell Biol. 4, 160e164.
Gandhi, S., Muqit, M.M., Stanyer, L., Healy, D.G., Abou-Sleiman, P.M., Hargreaves, I.,
Heales, S., Ganguly, M., Parsons, L., Lees, A.J., Latchman, D.S., Holton, J.L.,
Wood, N.W., Revesz, T., 2006. PINK1 protein in normal human brain and Par-
kinson’s disease. Brain 129, 1720e1731.
Gao, G., Vandenberghe, L.H., Wilson, J.M., 2005. New recombinant serotypes of AAV
vectors. Curr. Gene Ther. 5, 285e297.
Gasser, T., 2009. Mendelian forms of Parkinson’s disease. Biochim. Biophys. Acta
1792, 587e596.
Gautier, C.A., Kitada, T., Shen, J., 2008. Loss of PINK1 causes mitochondrial functional
defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U.S.A
105, 11364e11369.
Geisler, S., Holmstrom, K.M., Skujat, D., Fiesel, F.C., Rothfuss, O.C., Kahle, P.J.,
Springer, W., 2010. PINK1/Parkin-mediated mitophagy is dependent on VDAC1
and p62/SQSTM1. Nat. Cell Biol. 12, 119e131.
George, S., Mok, S.S., Nurjono, M., Ayton, S., Finkelstein, D.I., Masters, C.L., Li, Q.X.,
Culvenor, J.G., 2010. Alpha-synuclein transgenic mice reveal compensatory in-
creases in Parkinson’s disease-associated proteins DJ-1 and parkin and have
enhanced alpha-synuclein and PINK1 levels after rotenone treatment. J. Mol.
Neurosci. 42, 243e254.
Geraerts, M., Michiels, M., Baekelandt, V., Debyser, Z., Gijsbers, R., 2005. Upscaling of
lentiviral vectorproductionby tangentialflowfiltration. J.GeneMed. 7,1299e1310.
Gerard,M., Deleersnijder, A., Daniëls, V., Schreurs, S.,Munck, S., Reumers, V., Pottel, H.,
Engelborghs, Y., VandenHaute, C., Taymans, J.M., Debyser, Z., Baekelandt, V., 2010.
Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and
Parkinson’s disease-like pathology. J. Neurosci. 30, 2454e2463.
Gispert, S., Ricciardi, F., Kurz, A., Azizov, M., Hoepken, H.H., Becker, D., Voos, W.,
Leuner, K., Müller, W.E., Kudin,, A.P., Kunz, W.S., Zimmermann, A., Roeper, J.,
Wenzel, D., Jendrach, M., García-Arencíbia, M., Fernández-Ruiz, J., Huber, L.,
Rohrer,, H., Barrera,, M., Reichert, A.S., Rüb, U., Chen, A., Nussbaum, R.L.,
Auburger, G., 2009. Parkinson phenotype in aged PINK1-deficient mice is
accompanied by progressive mitochondrial dysfunction in absence of neuro-
degeneration. PLoS One 4, e5777.
Glasl, L., Kloos, K., Giesert, F., Roething, A., Di Benedetto,, B., Huhn, R., Zhang, J.,
Hafen, U., Zerle, J., Hofmann, A., de Angelis, M.H., Winklhofer, K.F., Hölter, S.M.,
Vogt Weisenhorn, D.M., Wurst, W., 2012. Pink1-deficiency in mice impairs gait,
olfaction and serotonergic innervation of the olfactory bulb. Exp. Neurol. 235,
214e227.
Gundersen, H.J., Jensen, E.B., 1987. The efficiency of systematic sampling in stere-
ology and its prediction. J. Microsc. 147, 229e263.
Haque, M.E., Thomas, K.J., D’Souza, C., Callaghan, S., Kitada, T., Slack, R.S., Fraser, P.,
Cookson, M.R., Tandon, A., Park, D.S., 2008. Cytoplasmic Pink1 activity protects
neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A 105,
1716e1721.
Haque, M.E., Mount, M.P., Safarpour, F., Abdel-Messih, E., Callaghan, S., Mazerolle, C.,
Kitada, T., Slack, R.S., Wallace, V., Shen, J., Anisman, H., Park, D.S., 2012. Inacti-
vation of Pink1 gene in vivo sensitizes dopamine-producing neurons to 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by
autosomal recessive Parkinson disease genes, Parkin or DJ-1. J. Biol. Chem. 287,
23162e23170.
M. Oliveras-Salvá et al. / Neurobiology of Aging 35 (2014) 2625e26362636He, L., Hannon, G.J., 2004. MicroRNAs: small RNAs with a big role in gene regulation.
Nat. Rev. Genet. 5, 522e531.
Heeman,, B., Van den Haute, C., Aelvoet, S.A., Valsecchi, F., Rodenburg, R.J.,
Reumers, V., Debyser, Z., Callewaert, G., Koopman, W.J., Willems, P.H.,
Baekelandt, V., 2011. Depletion of PINK1 affects mitochondrial metabolism,
calcium homeostasis and energy maintenance. J. Cell Sci. 124, 1115e1125.
Kamp, F., Exner, N., Lutz, A.K., Wender, N., Hegemann, J., Brunner, B., Nuscher, B.,
Bartels, T., Giese, A., Beyer, K., Eimer, S., Winklhofer, K.F., Haass, C., 2010. Inhi-
bition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin
and DJ-1. EMBO J. 29, 3571e3589.
Kitada, T., Pisani, A., Porter, D.R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P.,
Zhang, C., Pothos, E.N., Shen, J., 2007. Impaired dopamine release and synaptic
plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U.S.A
104, 11441e11446.
Klinkenberg, M., Thurow, N., Gispert, S., Ricciardi, F., Eich, F., Prehn, J.H., Auburger, G.,
Kogel, D., 2010. Enhanced vulnerability of PARK6 patient skin fibroblasts to
apoptosis induced by proteasomal stress. Neuroscience 166, 422e434.
Liu, W., Vives-Bauza, C., Acín-Peréz, R., Yamamoto, A., Tan, Y., Li, Y., Magrané, J.,
Stavaranche, M.A., Shaffer, S., Chang, S., Kaplitt, M.G., Huang, X.Y., Beal, M.F.,
Manfredi, G., Li, C., 2009. PINK1 defect causes mitochondrial dysfunction, pro-
teasomal deficit and alpha-synuclein aggregation in cell culture models of
Parkinson’s disease. PLoS One 4, e4597.
Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saïsho, K., Sou, Y.S., Saiki, S., Kawajiri, S.,
Sato, F., Kimura, M., Komatsu, M., Hattori, N., Tanaka, K., 2010. PINK1 stabilized
by mitochondrial depolarization recruits Parkin to damaged mitochondria and
activates latent Parkin for mitophagy. J. Cell Biol. 189, 211e221.
McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., Martins, I.,
Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B., Carter, B.J., Davidson, B.L.,
2008. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: impli-
cations for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U.S.A 105,
5868e5873.
Murakami, T., Moriwaki, Y., Kawarabayashi, T., Nagai, M., Ohta, Y., Geduchi, K.,
Kurata, T., Moromoto, N., Takehisa, Y., Matsubara, E., Ikeda, M., Harigaya, Y.,
Shoji, M., Takahashi, R., Abe, K., 2007. PINK1, a gene product of PARK6, accu-
mulates in alpha-synucleinopathy brains. J. Neurol. Neurosurg. Psychiatry 78,
653e654.
Narendra, D.P., Jin, S.M., Tanaka, A., Suen, D.F., Gautier, C.A., Shen, J., Cookson, M.R.,
Youle, R.J., 2010. PINK1 is selectively stabilized on impaired mitochondria to
activate Parkin. PLoS Biol. 8, e1000298.
Oliveras-Salvá, M., Van Rompuy, A.S., Heeman, B., Van den Haute, C., Baekelandt, V.,
2011. Loss-of-function rodent models for Parkin and PINK1. J. Parkinson’s Dis. 1,
229e251.
Oliveras-Salva, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S.,
D’Hooge, R., Van den Haute, C., Baekelandt, V., 2013. rAAV2/7 vector-mediated
overexpression of alpha-synuclein in mouse substantia nigra induces protein
aggregation and progressive dose-dependent neurodegeneration. Mol. Neuro-
degener. 8, 44.
Osorio, L., Gijsbers, R., Oliveras-Salva, M., Michiels, A., Debyser, Z., Van den Haute, C.,
Baekelandt, V., 2014. Viral vectors expressing a single microRNA-based short-
hairpin RNA result in potent gene silencing in vitro and in vivo. J. Biotechnol.
169, 71e81.
Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., Wolozin, B., 2000. The
A53T alpha-synuclein mutation increases iron-dependent aggregation and
toxicity. J. Neurosci. 20, 6048e6054.
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M., Ghafourifar, P., 2008. Mito-
chondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life
Sci. 65, 1272e1284.
Park, J., Lee, S.B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.M.,
Chung, J., 2006. Mitochondrial dysfunction in Drosophila PINK1 mutants is
complemented by parkin. Nature 441, 1157e1161.
Paxinos, G., Franklin, K.B.J., 2001. The Mouse Brain in Stereotaxic Coordinates. Ac-
ademic Press, San Diego.
Plun-Favreau, H., Klupsch, K., Moisoi, N., Gandhi, S., Kjaer, S., Frith, D., Harvey, K.,
Deas, E., Harvey, R.J., McDonald, N., Wood, N.W., Martins, L.M., Downward, J.,
2007. The mitochondrial protease HtrA2 is regulated by Parkinson’s disease-
associated kinase PINK1. Nat. Cell Biol. 9, 1243e1252.
Pridgeon, J.W., Olzmann, J.A., Chin, L.S., Li, L., 2007. PINK1 protects against
oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol.
5, e172.Sallinen, V., Kolehmainen, J., Priyadarshini, M., Toleikyte, G., Chen, Y.C., Panula, P.,
2010. Dopaminergic cell damage and vulnerability to MPTP in Pink1 knock-
down zebrafish. Neurobiol. Dis. 40, 93e101.
Samann, J., Hegermann, J., von Gromoff, E., Eimer, S., Baumeister, R., Schmidt, E.,
2009. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress
response and neurite outgrowth. J. Biol. Chem. 284, 16482e16491.
Samaranch, L., Lorenzo-Betancor, O., Arbelo, J.M., Ferrer, I., Lorenzo, E., Irigoyen, J.,
Pastor, M.A., Marrero, C., Isla, C., Herrera-Henriquez, J., Pastor, P., 2010. PINK1-
linked parkinsonism is associated with Lewy body pathology. Brain 133,
1128e1142.
Sandebring, A., Thomas, K.J., Beilina, A., van der Brug, M., Cleland, M.M., Ahmad, R.,
Miller, D.W., Zambrano, I., Cowburn, R.F., Behbahani, H., Cedazo-Mingues, A.,
Cookson, M.R., 2009. Mitochondrial alterations in PINK1 deficient cells are
influenced by calcineurin-dependent dephosphorylation of dynamin-related
protein 1. PLoS One 4, e5701.
Schmitz, C., Hof, P.R., 2005. Design-based stereology in neuroscience. Neuroscience
130, 813e831.
Shin, J.H., Ko, H.S., Kang, H., Lee, Y., Lee, Y.I., Pletinkova, O., Troconso, J.C.,
Dawson, V.L., Dawson, T.M., 2011. PARIS (ZNF746) repression of PGC-1alpha
contributes to neurodegeneration in Parkinson’s disease. Cell 144,
689e702.
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M.,
1997. Alpha-synuclein in Lewy bodies. Nature 388, 839e840.
Sun, D., Melegari, M., Sridhar, S., Rogler, C.E., Zhu, L., 2006. Multi-miRNA hairpin
method that improves gene knockdown efficiency and provides linked multi-
gene knockdown. Biotechniques 41, 59e63.
Taymans, J.M., Van den Haute, C., Baekelandt, V., 2006. Distribution of PINK1 and
LRRK2 in rat and mouse brain. J. Neurochem. 98, 951e961.
Todd, A.M., Staveley, B.E., 2008. Pink1 suppresses alpha-synuclein-induced pheno-
types in a Drosophila model of Parkinson’s disease. Genome 51, 1040e1046.
Todd, A.M., Staveley, B.E., 2012. Expression of Pink1 with alpha-synuclein in the
dopaminergic neurons of Drosophila leads to increases in both lifespan and
healthspan. Genet. Mol. Res. 11, 1497e1502.
Valente, E.M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A.E., Caputo, V., Romito, L.,
Albanese, A., Dallapiccola, B., Bentivoglio, A.R., 2004a. PINK1 mutations are
associated with sporadic early-onset parkinsonism. Ann. Neurol. 56,
336e341.
Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S.,
Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G., Albanese, A., Nussbaum, R.,
González-Maldonado, R., Deller, T., Salvi, S., Cortelli, P., Gilks, W.P.,
Latchman, D.S., Harvey, R.J., Dallapiccola, B., Auburger, G., Wood, N.W., 2004b.
Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Sci-
ence 304, 1158e1160.
Van den Haute, C., Eggermont, K., Nuttin, B., Debyser, Z., Baekelandt, V., 2003.
Lentiviral vector-mediated delivery of short hairpin RNA results in persistent
knockdown of gene expression in mouse brain. Hum. Gene Ther. 14,
1799e1807.
Van der Perren, A., Toelen, J., Carlon, M., Van den Haute, C., Coun, F., Heeman, B.,
Reumers, V., Vandenberghe, L.H., Wilson, J.M., Debyser, Z., Baekelandt, V.,
2011. Efficient and stable transduction of dopaminergic neurons in rat sub-
stantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 18,
517e527.
Wang, H.L., Chou, A.H., Wu, A.S., Chen, S.Y., Weng, Y.H., Kao, Y.C., Yeh, T.H., Chu, P.J.,
Lu, C.S., 2011. PARK6 PINK1 mutants are defective in maintaining mitochondrial
membrane potential and inhibiting ROS formation of substantia nigra dopa-
minergic neurons. Biochim. Biophys. Acta 1812, 674e684.
Xi, Y., Ryan, J., Noble, S., Yu, M., Yilbas, A.E., Ekker, M., 2010. Impaired dopaminergic
neuron development and locomotor function in zebrafish with loss of pink1
function. Eur. J. Neurosci. 31, 623e633.
Yang, Y., Gehrke, S., Imai, Y., Huang, Z., Ouyang, Y., Wang, J.W., Yang, L., Beal, M.F.,
Vogel, H., Lu, B., 2006. Mitochondrial pathology and muscle and dopaminergic
neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by
Parkin. Proc. Natl. Acad. Sci. U.S.A 103, 10793e10798.
Zhou, H., Falkenburger, B.H., Schulz, J.B., Tieu, K., Xu, Z., Xia, X.G., 2007. Silencing of
the Pink1 gene expression by conditional RNAi does not induce dopaminergic
neuron death in mice. Int. J. Biol. Sci. 3, 242e250.
Zhou, C., Huang, Y., Shao, Y., May, J., Prou, D., Perier, C., Dauer, W., Schon, E.A.,
Przedborski, S., 2008. The kinase domain of mitochondrial PINK1 faces the
cytoplasm. Proc. Natl. Acad. Sci. U.S.A 105, 12022e12027.
